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Methods:We conducted a longitudinal study using CF registries in Denmark and the UK. 471 individuals with a
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person were included from Denmark and the UK respectively. We estimated the effect of seasonality on percent
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iation in percent predicted FEV1 around the yearly averagewas estimated to be 0.1 percentage points (95%CI 0 to
0.21) and 0.14 percentage points (95%CI 0 to 0.29) in Denmark and the UK, respectively. When considering pos-
sible step-like changes between the four seasons, we found that lung function was higher in spring compared to
winter in the UK (0.34 percentage points, 95%CI 0.1 to 0.59) though the differencewas not of clinical signiﬁcance.
Conclusion: In both the UK and Denmark there may be small seasonal changes in lung function but this effect is
not of clinical importance.
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Seasonality
Season
Fluctuation
Percent predicted FEV11. Introduction
Seasonal patterns in respiratory outcomes in conditions such as
asthma and COPD are well recognised in terms of lung function, admis-
sions to hospital and deaths [1,2]. Furthermore, theories about seasonal
variations in cystic ﬁbrosis (CF) morbidity are common, though they
often rely more on shared observations and clinical hunches than hard
evidence. For example in the early days of CF medicine a puzzling sea-
sonal trend in CF mutations at birth was observed [3], but quickly
debunked as a case of ascertainment bias [4]. It is perhaps not surprising
that theories on climate and seasonal variations are common in CF;
weather is a popular topic, probably because it is a shared experience,
ripe for pattern-ﬁnding [5,6]. More importantly, many of the signiﬁcant
risk factors associated with CF pulmonary disease display seasonal var-
iability. The most well-known examples are seasonal inﬂuenza out-
breaks, which lead to increased mortality in the general population [7]üter).
on behalf of European Cystic Fibrosis Socand in CF populations, where rates of pulmonary exacerbations in-
crease during epidemics [8]. Likewise, acquisition of Pseudomonas
aeruginosa has been shown to exhibit seasonal variation, such that
US children with CF in temperate and continental climate zones
have a higher incidence in summer months [9], with no difference
among children in dry climate zones. Conversely, an early Danish
study showed more Pseudomonas acquisition in winter [10].
In the context of amultitude of interacting risk and protective fac-
tors inﬂuencing CF outcomes over time, and given the inherent vari-
ability in lung function measures in people with CF [11], any
seasonality effect on risk factors and clinical outcomes is difﬁcult to
isolate. Furthermore it is unclear whether seasonality affects lung
function, themain clinicalmorbidity indicator in CF.We therefore de-
veloped a longitudinal model for evaluating lung function changes
over time in people with CF, and applied it to two CF populations in
Northern Europe. The aim of our study was to assess seasonal ﬂuctu-
ations in lung function at the population level.iety. This is an open access article under theCCBY license (http://creativecommons.org/
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391T. Qvist et al. / Journal of Cystic Fibrosis 18 (2019) 390–3952. Methods
2.1. Study design, setting, data sources and participants
We carried out longitudinal analyses of lung function in individuals
with CF captured in the Danish and UK CF registers between 1974 and
2014 and between 1996 and 2015, respectively. Individuals born before
1969 were excluded to reduce the inﬂuence of survivor bias [11]. Lung
function measurements taken post-transplant or before the age of ﬁve
were also excluded.
In Denmark, individualswith CFwere followed upmonthly in one of
the two CF centres in Copenhagen and Aarhus. Measurements were re-
corded in the Danish CF Patient Registry, whichwas established in 1974
but includes records going back to the 1960s and has an almost com-
plete record of all individuals living with CF in Denmark from 1990 on-
wards when CF carewas centralised. In the UK individualswith CFwere
seen in one of 50 specialist CF centres. The recommendation in the UK is
that the annual encounter data submitted to the Registry is from a clinic
visit roughly 12months after the previous entry andwhen the patient is
clinically stable. Records date back to the 1990s and are estimated to
capture 99% of the current UK CF population (see [12] for more details).
In both countries, the follow-up reviews included evaluation of clinical
status, lung function, and microbiology of respiratory tract secretions.
2.2. Outcome, exposure and covariates
Our outcome of interest was lung function from age 5 as measured
by percent of predicted forced expiratory volume in one second
(%FEV1). Pulmonary function tests were performed at the monthly/an-
nual review visits. Measurements were expressed as a percentage of
predicted values for sex and height in Denmark [13,14], and as a per-
centage of predicted values for sex, age, height and ethnicity in the UK
[15]. Our exposure of interest was the time of year of measurement.
Two variables were created for this. One was a 4 level categorical vari-
able for the season during which the review visit took place, where De-
cember, January, and February were coded as ‘winter’, March, April, and
May as ‘spring’, June, July and August as ‘summer’ and September, Octo-
ber, November as ‘autumn’. Our other approach was to use the day of
year of the review visit, where 1st January was day zero and 31st De-
cember was day 365/366.
In both populations we adjusted for the following time-invariant co-
variates: age at diagnosis, birth cohort, pancreatic insufﬁciency (PI,
coded as 0 or 1 according to whether PI was ever diagnosed), genotype
(coded as the number of F508del alleles (0, 1 or 2)) and sex.We also ad-
justed for age and CF related diabetes (CFRD) aswell as chronic pseudo-
monas as time varying covariates (the latter two coded as 0 or 1). In the
UK we additionally included deprivation z-score based on the index of
multiple deprivation (IMD), ethnicity (grouped as White, Black, North
East Asian, South East Asian, Other/Mixed) and a binary indicator for di-
agnosis by new-born screening.
2.3. Statistical analysis
We developed a longitudinal model for lung function in Denmark
and in the UK using a previously published approach [11,16]. In brief,
we developed a linear model for the population average lung function,
in which both the intercept at age 5 and the slope depend on the
time-invariant covariates and the slope additionally depends on CFRD
and chronic pseudomonas. The lung function measurements within an
individual are correlated, but as the healthcare systems differ between
countries, we cannot assume the underlying stochastic process to be
the same in the Danish and UK CF populations and we therefore
modelled the data from each country separately. Due to the different
follow-up procedure, the short term-correlation that is captured inDen-
mark cannot be quantiﬁed in the UK. Therefore, we used different
models for the longitudinally structured correlation; in Denmark we
Table 2
Number of FEV1 measurements (%) taken in the four season and their unadjusted mean values across all individuals (standard deviation).
Country Winter Spring Summer Autumn
Number of
measurements
Mean value
(% predicted)
Number of
measurements
Mean value
(% predicted)
Number of
measurements
Mean value
(% predicted)
Number of
measurements
Mean value
(% predicted)
Denmark 16,104 (25%) 74.97 (25.18) 16,505 (25%) 74.87 (25.2) 16,014 (24%) 74.87 (25.35) 16,851(26%) 74.95 (25.21)
UK 14,762 (21%) 71.1 (23.06) 16,084 (23%) 71.03 (23.04) 17,565 (25%) 71.11 (23.0) 22,256 (31%) 71.17 (23.17)
392 T. Qvist et al. / Journal of Cystic Fibrosis 18 (2019) 390–395used an exponentially decaying function of time difference [11]
whereas in the UKwe used a random slopemodel [16]. Bothmodels in-
cluded a random intercept to take into account the between individual
heterogeneity in baseline lung function. See SupplementaryMaterial for
the model equation and further details.
To assess whether there were seasonal ﬂuctuations in lung function,
we added the time of year as a time-varying covariate to the model
using two different approaches. In the ﬁrst approachwe used a categor-
ical variable with the levels ‘winter’, ‘spring’, ‘summer’ and ‘autumn’ as
an explanatory variable of lung function. We used ‘winter’ as the refer-
ence level as it may be plausible that lung function is lowest during this
time. In the second approach, we modelled smooth changes in lung
function according to season using a sine wave where the period is
one year (365.25 days) and the amplitude and horizontal shift are
model parameters to be estimated from the data (see Supplementary
Material for further details).
We ﬁtted themodel usingmaximum likelihood estimation (ML) and
the R package nlme [17]. Statistical signiﬁcance of a seasonal effect was
assessed with a likelihood ratio test. Conﬁdence intervals for the cate-
gorical ‘season’ variable were constructed using the R function inter-
vals.lme, which uses a normal approximation of the ML estimators for
the average differences in lung function in spring, summer and autumn
compared to winter. For the approach using the sine wave, conﬁdence
intervals for the amplitude and the phase shift were also based on a nor-
mal approximation (more details are given in the SupplementaryMate-
rial). Only individuals with complete information on the baseline
covariates were included in the analysis.2.4. Robustness test and additional analysis
As a robustness test, we repeated the analysis dropping measure-
ments taken from individuals born before 1991 in the UK to reduce
any remaining potential inﬂuence of survivor bias in this population.
To assess whether the seasonal patterns differed between children
and adults we re-ﬁtted themodels with the sinewave in both countries
including an interaction term between the sine function and an indica-
tor for b or ≥ 18 years of age.2.5. Ethical considerations
NHS research ethics approval (HuntingdonResearch Ethics Commit-
tee 07/Q0104/2)was granted for the collection of data into the UK data-
base. The Cystic Fibrosis Trust database committee approved the use of
anonymised data in this study. In Denmark the study was approved by
the Danish Data Protection Agency (ﬁle no. 2008-41-2682).Table 3
Parameter estimates (95% conﬁdence intervals) for the seasonal effects on percent predicted F
Parameters Denmark
Estimates
Categorical ‘season’ variable (percentage points;
reference level = winter)
Spring 0.01 (−0.15 t
Summer 0.1 (−0.07 to
Autumn 0.13 (−0.03 t
Amplitude of sine wave (percentage points) 0.1 (0 to 0.21
Horizontal shift of sine wave (days) 148.47 (−1822.6. Role of the funding source
This work was funded by the UK Cystic Fibrosis Trust through the
Strategic Research Centre “CF EpiNet: Harnessing data to improve
lives”. DTR was also funded by the MRC on a Clinician Scientist Fellow-
ship (MR/P008577/1). The funder was not involved in the study design,
data collection, data analysis, data interpretation, or in thewriting of the
report. The corresponding author had full access to all the data in the
study and ﬁnal responsibility for the decision to submit for publication.
3. Results
3.1. Participants
485 individuals in the Danish CF Registry were born between 1969
and 2009 all of whom had at least one lung function measurement
after the age of 5. Age at diagnosis was missing in 14 individuals who
were thus excluded from the analysis. The median follow-up time was
12.6 years with a median of 104 FEV1 measures per patient. In the UK
CF Registry 10,269 individuals were born between 1969 and 2010;
9667 had lung function measurements after the age of 5 out of which
7586 had complete covariate data (see Supplementary Material for a
comparison of the demographics). The median follow-up time in the
UK study population was 10.4 years with a median of nine FEV1 mea-
sures. Table 1 gives the demographics of the study population stratiﬁed
by birth cohort. Follow-up visits were approximately evenly distributed
across the year in Denmark and increased slightly in frequency towards
the end of the year in the UK (see Table 2).
3.2. Seasonal effects on lung function
In the Danish population the overall effect of seasonality on lung
function was not signiﬁcant at the 5% level in either the model with
the categorical season variable or the model with the sine function. Pa-
rameter estimates, conﬁdence intervals and likelihood-ratio test p-
values are given in Table 3. Lung function was not found to differ signif-
icantly between spring, summer or autumn and winter. Using the sine
wave to capture smoothly varying seasonal ﬂuctuations, we estimated
an amplitude of 0.1 percentage points (95%CI 0 to 0.21). The horizontal
shift was estimated to be 148.47 days (95%CI -182.32 to 182.61). Thus
lung function was estimated to peak on the 28th August and dip on
the 27th February. Conﬁdence intervals for both dates covered the en-
tire year. Amplitude and horizontal shift are however correlated; Fig. 1
shows their joint 95% conﬁdence region. Only for a horizontal shift
N63 days or less than −130 days, which equates to lung function
peaking between June and October, was the upper 95% bound for the
amplitude N0.05 (see Supplementary Material for details).EV1 and p-values from the Likelihood ratio test.
UK
p-value Estimates p-value
o 0.18) 0.34 0.34 (0.1 to 0.58) 0.06
0.28) 0.21 (−0.04 to 0.45)
o 0.2) 0.17 (−0.06 to 0.39)
) 0.07 0.14 (0 to 0.29) 0.07
.32 to 182.61) 66.2 (−182.25 to 179.51)
Fig. 1. Joint 95% conﬁdence region of the horizontal shift and amplitude in Denmark and the UK.
393T. Qvist et al. / Journal of Cystic Fibrosis 18 (2019) 390–395In the UK, the overall effect of seasonality on lung function was only
marginally not signiﬁcant at the 5% level. Lung function was estimated
to be signiﬁcantly higher in spring compared towinter (0.34 percentage
points (95%CI 0.1 to 0.59)), whereas there was no signiﬁcant difference
between lung function in summer or autumn andwinter. Using the sine
function, we estimated an amplitude of 0.14 percentage points (95%CI 0
to 0.29). The horizontal shift was estimated to be 66.2 days (95%CI
-182.25 to 179.51). Thus lung function was estimated to peak on the
7th June and dip on the 6th December, with conﬁdence intervals for
both dates covering the entire year. However, the upper 95% conﬁdence
limit for the amplitude was N0.05 only for horizontal shifts between
−26 and 157 days, which equates to lung function peaking between
March and September (see Fig. 1).
Fig. 2 shows the modelled cyclical seasonal ﬂuctuation in percent
predicted FEV1 in both countries.
Tables S2 and S3 in the Supplementary Material give all parameter
estimates and 95% conﬁdence intervals for the covariates included inFig. 2. Estimated seasonal ﬂuctuation in percent predicted FEV1. The shaded regiothe model; Tables S4 and S5 in the Supplementary Material give the es-
timated Variance-Covariance parameters.3.3. Robustness test and additional analysis
Repeating the analysis in the UK only on individuals with CF born
after 1991 reduced the point estimates, but the conﬁdence intervals
were compatible with the previously presented results. Details are
given in the Supplementary Material.
In the additional analysis, which included an interaction effect be-
tween the sine function and an indicator for b or ≥ 18 years of age, we
did not ﬁnd any signiﬁcant differences in seasonal patterns in lung func-
tion between children and adults. See Supplementary Material for
details.ns are the 95% conﬁdence regions. 0 on the x-axis represents the 1st January.
394 T. Qvist et al. / Journal of Cystic Fibrosis 18 (2019) 390–3954. Discussion
We carried out a longitudinal analysis of lung function change over
time in two national Northern European CF populations and found
that there is no clinically important seasonal variation in lung function.
Given the reported seasonal ﬂuctuation of some risk factors for ad-
verse CF outcomes, such as inﬂuenza epidemics and PA acquisition,
the lack of any substantive seasonal variation in lung function is perhaps
an unexpected ﬁnding. Rates of pulmonary exacerbations have been re-
ported as being more frequent during inﬂuenza epidemics [8]. Acquisi-
tion of Pseudomonas aeruginosa has also been shown to demonstrate
seasonal variation, either with a higher incidence in summer [9], or in
winter [10], depending on the geographical location.
A clear seasonal variability in non-inﬂuenza respiratory viruses has
also been observed in CF, but this season effect does not translate to pul-
monary exacerbations [18]. A study from the CF Foundation National
Patient Registry showed thatMRSAwasmore frequently acquired in au-
tumn and winter, whereas A. xylosoxidans acquisition was lower in
spring. For H. inﬂuenzae, winter and spring were associated with higher
acquisition. No seasonal variation was observed for S. maltophilia acqui-
sition [19]. It is well established that there are higher mould counts in
the outdoor environment in autumn and this has been suspected to
lead to higher risks of pulmonary Aspergillus and ABPA [20], but other
reports have found that even adequate climate conditions forAspergillus
are in themselves not ideal conditions for increased acquisition [21].
Other environmental factors that show seasonal variability, but where
inﬂuence on morbidity in CF is unclear, include ambient temperatures
[22], air humidity and domestic water temperature [23]. All of these
might be expected to affect the prevalence or virulence of well-known
CF pathogens, but clear evidence is lacking. The connection between
season, pathogen acquisition and lung function in CF is thus clearly
not straightforward.
In addition vitamin-D levels are also known to ﬂuctuatewith sun ex-
posure during the calendar year. Such ﬂuctuationsmight be expected to
be mirrored in a hard outcome such as lung function, but this link has
also turned out not to be direct [24]. Dehydration during warm weeks
is a risk factor for obstipation, but not for lung function [25]. Altered
clinic opening hours during vacation periods, patient travel patterns
during the calendar year, and respiratory outbreaks during seasonal
CF community events [26,27] could all effect groups of patients, but
the effect on a population level is uncertain.
There are a number of potential explanations for the lack of seasonal
variation in lung function in our study. Firstly, the size of any seasonal
ﬂuctuation in risk factors and subsequent impact on lung function
may have previously been overestimated, or other, differently distrib-
uted and more dominant effects may lessen their impact. Secondly, it
is possible that CF maintenance therapy and exacerbationmanagement
in the UK and Denmark is able to mitigate any negative effects of the
winter season. A recent study in the US found that patients in the CFF
Registry had a higher lung function in January compared to July. Similar
to ourﬁndings, the difference at the population levelwas small and clin-
ically insigniﬁcant at an average of about 1.2%FEV1 [28]. We found lung
function to behigher in spring than inwinter in theUKbut did not ﬁnd a
statistically signiﬁcant difference between winter and summer. The US
study also showed that the effect of annual average temperatures on
lung function dominated over seasonal ﬂuctuations. The differences in
climate between northern Europe and the US may therefore go some
way in explaining any differences in ﬁndings.
4.1. Strengths and weaknesses
A strengthof this analysis is thatwe analysed twowell-characterised
population-level CF registry datasets, with consistent ﬁndings across
the two analyses, using up to date statistical approaches appropriate
to the differing data collection pattern in the two datasets. The Danish
dataset hadmonthly clinic visit frequency facilitating precise estimationof change within individuals over time. By contrast, the UK dataset
contained many more individuals but had less frequent follow-up
throughout the year, allowingmore precise estimation of the cross-sec-
tional effect of seasonality. A limitation of our analysis is that we did not
have data on the precise date of onset of PA or other respiratory patho-
gens in either dataset, and thus were not able to assess if there was sea-
sonal variation in these risk factors. Similarly, we did not have data on
potential changes in CFmanagement throughout the year,making it im-
possible to determinewhether responses from clinical staffmitigate any
potentially negative effects of seasonal changes in pathogens and envi-
ronmental factors on lung function.
5. Conclusion
Our ﬁndings from the analysis of national CF registry populations in
Denmark and the UK suggest that there is no clinically signiﬁcant sea-
sonality effect on lung function.
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